Trulicity (dulaglutide) / Eli Lilly - LARVOL DELTA

SURPASS-CVOT: Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (clinicaltrials.gov) - P=N/A | N=70000 | Active, not recruiting | Sponsor: Brigham and Women's Hospital | N=50000 ➔ 70000 | Trial completion date: Jun 2025 ➔ Mar 2026 | Trial primary completion date: Jan 2025 ➔ Dec 2025

Enrollment change • Trial completion date • Trial primary completion date • Cardiovascular • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Impact of GLP-1 agonists on cardiovascular outcomes in patients with sickle cell anemia: A propensity score matched retrospective cohort study (ASH 2025) - "The Glucagon-like peptide-1 receptor agonists (GLP-1 agonists) semaglutide, liraglutide, and dulaglutide have been shown to reduce the risk of major adverse CV events in large-scale prospective trials of patients with type two diabetes mellitus and high CV risk. Our study confirms that SCD is associated with worse CV outcomes and that the use of GLP1 agonists significantly reduces the risk of these endpoints in patients with SCD. These results are comparable to other studies showing worse CV outcomes in SCD patients and add to the growing field of data demonstrating improved CV outcomes with the use of GLP1 agonists. More prospective studies are needed to assess the impact of GLP1 agonist therapy on rates of adverse CV outcomes in various patient populations, including those with hemoglobinopathies."

Retrospective data • Anemia • Cardiovascular • Congestive Heart Failure • Diabetes • Genetic Disorders • Heart Failure • Hematological Disorders • Metabolic Disorders • Myocardial Ischemia • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Sickle Cell Disease

Changes in Fibroblast Growth Factor 21 Levels Associated with Alcohol Consumption and Smoking Cessation. (PubMed, Endocr Connect) - "Study 2: 144 alcohol-drinking men or women undergoing 12-week intervention of glucagon-like peptide 1 (GLP-1) receptor agonist dulaglutide vs placebo on smoking and alcohol cessation...Our findings demonstrate a dynamic response in FGF21 levels, with acute moderate alcohol consumption inducing elevated FGF21 levels, and cessation of drinking lowering FGF21 levels, indicative of potential liver recovery. No effect of cigarette smoking cessation on plasma FGF21 levels was observed."

Journal • Hepatology • Metabolic Disorders • Tobacco Cessation • FGF21

Impact of Discontinuing GLP-1 Receptor Agonists for Two Weeks Prior to Upper Endoscopy on the Risk of Gastric Retention (clinicaltrials.gov) - P=N/A | N=16509 | Not yet recruiting | Sponsor: Fudan University

New trial

The effects of glucagon-like peptide-1 receptor agonists (GLP1-RAs) on alcohol-related outcomes: a systematic review and meta-analysis. (PubMed, Addict Sci Clin Pract) - "Observational studies suggest a decrease in alcohol-related events, but RCTs have effects on alcohol consumption and craving that remain non-significant. Larger RCTs are needed."

Journal • Retrospective data • Addiction (Opioid and Alcohol)

The concentration-dependent protective effects by new generation hypoglycemic agents on delirium, depression, dementia and coma: evidence from a network meta-analysis. (PubMed, J R Soc Med) - "This analysis highlights agent-specific neuroprotective profiles: SGLT2 inhibitors, especially high-dose dapagliflozin, may mitigate the onset of delirium and depression, while GLP-1 receptor agonists, notably dulaglutide and liraglutide, may enhance cognitive function. These findings warrant consideration in selecting antihyperglycemic therapies for individuals at elevated neuropsychiatric risk."

Journal • Retrospective data • Alzheimer's Disease • CNS Disorders • Dementia • Depression • Diabetes • Mental Retardation • Metabolic Disorders • Mood Disorders • Psychiatry • Type 2 Diabetes Mellitus

GLP-1 receptor agonists reduce body mass index and total daily insulin dose in youth with type 1 diabetes: a retrospective cohort study. (PubMed, J Pediatr Endocrinol Metab) - "This first longitudinal report of GLP-1RA use in youth with T1D and obesity shows clinically meaningful improvements in weight, glycemia, and insulin requirements, supporting the potential role of GLP-1RA as adjunct therapy. Larger prospective studies are needed to guide clinical practice."

Journal • Retrospective data • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Pediatrics • Type 1 Diabetes Mellitus

CER-4-T2D: Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study (clinicaltrials.gov) - P=N/A | N=781430 | Active, not recruiting | Sponsor: Brigham and Women's Hospital | Trial completion date: Jul 2024 ➔ Jul 2026 | Trial primary completion date: Jul 2024 ➔ Jan 2026

HEOR • Trial completion date • Trial primary completion date • Cardiovascular • Diabetes • Diabetic Nephropathy • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Effects of glucagon-like peptide-1 receptor agonists on alcohol consumption: a systematic review and meta-analysis. (PubMed, EClinicalMedicine) - "GLP-1 RAs studied were Semaglutide, liraglutide, dulaglutide, exenatide, and tripeptide. Large, dedicated RCTs are needed to confirm efficacy and define optimal therapeutic strategies. No funding was received for this study."

Journal • Retrospective data • Addiction (Opioid and Alcohol) • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis: A Narrative Review. (PubMed, Cureus) - "Its therapeutic potential was long realized, leading to the development of the first GLP-1 receptor agonist, exenatide, followed by liraglutide, dulaglutide, semaglutide, and tirzepatide...Alongside resmetirom, semaglutide is currently approved for the treatment of non-cirrhotic MASH with moderate-to-advanced fibrosis. Safety considerations include gastrointestinal intolerance, hypoglycemia, rare pancreaticobiliary events, and theoretical concerns of thyroid C-cell tumors, though human risk remains minimal. In summary, semaglutide extends the armamentarium of the hepatologist against the most common liver disease worldwide."

Journal • Review • Cardiovascular • Diabetes • Fibrosis • Genetic Disorders • Hepatology • Hypoglycemia • Immunology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Oncology • Thyroid Gland Carcinoma • Type 2 Diabetes Mellitus

Cardiorenal Safety Markers With Injectable Glucagon-Like Peptide-1 (GLP-1) Agonists in Type 2 Diabetes: A Network Meta-Analysis. (PubMed, Cureus) - "Efpeglenatide ranked highest for both MACE (OR: 0.74; 95% CI: 0.62-0.87; SUCRA: 81.5%) and renal outcomes (OR: 0.68; 95% CI: 0.57-0.81; SUCRA: 81.33%), underscoring its clinical significance over other effective agents such as albiglutide and semaglutide. Albiglutide, semaglutide, dulaglutide, and liraglutide also provided significant benefits, albeit with lower rankings. No major inconsistency or publication bias was detected. In conclusion, this NMA reinforces the class-wide cardiorenal benefits of GLP-1 receptor agonists while emphasizing variations in efficacy among individual agents, the limited evidence base for certain drugs, and the need for future head-to-head trials specifically designed to evaluate cardiovascular and renal endpoints."

Journal • Retrospective data • Review • Cardiovascular • Chronic Kidney Disease • Diabetes • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Regulator releases new safety warnings for weight loss and diabetes drugs including Ozempic, Wegovy and Mounjaro (News.com.au) - "The safety alert issued by the regulator on Monday details links to two separate safety issues; the potential risk of suicidal thoughts, and reduced effectiveness of oral contraception...It relates to GLP-1 and dual GIP/GLP-1 receptor agonists which are primarily prescribed to manage type 2 diabetes and obesity, and are marketed in Australia as Ozempic (semaglutide) Wegovy (semaglutide), Saxenda (liraglutide), Trulicity (dulaglutide) and Mounjaro (tirzepatide)."

Non-US regulatory • Obesity • Type 2 Diabetes Mellitus

Tirzepatide is Associated with Reduced Risk of Primary Open-Angle Glaucoma and Ocular Hypertension in Patients with Type 2 Diabetes. (PubMed, Am J Ophthalmol) - "Tirzepatide use was associated with a significantly reduced risk of developing POAG, OHTN, and need for first-line glaucoma treatment compared to selective GLP-1 RAs in patients with T2DM. These findings suggest a potential additional ocular benefit of tirzepatide and support further investigation into its role in glaucoma management."

Journal • Cardiovascular • Diabetes • Glaucoma • Metabolic Disorders • Ophthalmology • Type 2 Diabetes Mellitus

Acute Pancreatitis After Initiating Dulaglutide in a Patient Previously Treated With a DPP-4 Inhibitor: Case Report From Palestine. (PubMed, Case Rep Gastrointest Med) - "GLP-1 receptor agonists are advantageous for the management of diabetes and obesity but may precipitate acute pancreatitis in predisposed individuals. Clinicians should be aware of this potential risk and promptly investigate any patient who presents with signs of acute abdominal pain during GLP-1 therapy."

Journal • Cardiovascular • Constipation • Diabetes • Diabetic Nephropathy • Dyslipidemia • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Hypertension • Metabolic Disorders • Obesity • Pain • Pancreatitis • Renal Disease • Type 2 Diabetes Mellitus

GLP-1 receptor agonists on WHO-EML 2025 list: major breakthrough bounded by persistent challenge. (PubMed, J Diabetes Metab Disord) - "Notably, the inclusion of glucagon-like peptide-1 (GLP-1) receptor agonists-semaglutide, liraglutide, dulaglutide-and the dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, tirzepatide, represents a paradigm shift in the management of type 2 diabetes mellitus (T2DM) and obesity...However, challenges persist, including financial constraints, limited healthcare infrastructure, and risks of irrational use, particularly for obesity alone. Effective implementation through national policies, training, and rational prescribing frameworks is essential to translating this global milestone into tangible public health benefits and to reducing the growing burden of diabetes and obesity worldwide."

Journal • Cardiovascular • Chronic Kidney Disease • Cystic Fibrosis • Dermatology • Diabetes • Genetic Disorders • Hematological Disorders • Hemophilia • Immunology • Infectious Disease • Metabolic Disorders • Nephrology • Obesity • Oncology • Psoriasis • Pulmonary Disease • Rare Diseases • Renal Disease • Respiratory Diseases • Type 2 Diabetes Mellitus

Acute Kidney Injury from Mononuclear Cell-Predominated Interstitial Nephritis After Introduction of a Glucagon-Like Peptide-1 Receptor Agonist: A Case Report. (PubMed, Am J Case Rep) - "CASE REPORT A 63-year-old woman with stage 3b diabetic kidney disease and depressive disorder was prescribed dulaglutide 0.75 mg/week subcutaneously in August 2023 due to persistent albuminuria despite receiving the maximum tolerated dose of azilsartan...Azilsartan and chlorthalidone could then be successfully rechallenged...Nevertheless, this does not prevent the prescription of GLP-1 RAs to alleviate DKD progression in certain patients. Treatment includes drug discontinuation and steroid therapy in non-responders."

Journal • Acute Kidney Injury • CNS Disorders • Depression • Diabetic Nephropathy • Infectious Disease • Nephrology • Psychiatry • Renal Disease

OCULUS: Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy (clinicaltrials.gov) - P4 | N=69 | Completed | Sponsor: The Cleveland Clinic | Suspended ➔ Completed | Trial completion date: Sep 2025 ➔ May 2025

Trial completion • Trial completion date • Diabetes • Gastrointestinal Disorder • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Dulaglutide as a Bridging Therapy Before Insulin for Diabetes Following Pancreatectomy on Congenital Hyperinsulinism. (PubMed, JCEM Case Rep) - "He has been free from exogenous insulin for more than 4 years under dulaglutide. In conclusion, in selected patients with CHI/PPD and reserved β-cell function, dulaglutide may serve as a bridging therapy before insulin introduction."

Journal • Anorexia • CNS Disorders • Diabetes • Hypoglycemia • Metabolic Disorders • Vascular Neurology

Cardiovascular Effectiveness of Semaglutide Versus Dulaglutide in Type 2 Diabetes. (PubMed, Pharmacoepidemiol Drug Saf) - "This target trial emulation did not provide evidence for a substantial difference in cardiovascular outcomes between individuals with type 2 diabetes initiating semaglutide and dulaglutide."

Clinical • Journal • Cardiovascular • Congestive Heart Failure • Diabetes • Heart Failure • Ischemic stroke • Metabolic Disorders • Myocardial Infarction • Type 2 Diabetes Mellitus

GLP1 and GIP Receptor Agonists: Effects on the Gastrointestinal Tract and Management Strategies for Primary Care Physicians. (PubMed, Mayo Clin Proc) - "Type 2 diabetes and obesity drive significant morbidity, mortality, and health care costs in the United States...Long-acting formulations (eg, semaglutide, dulaglutide, and tirzepatide, among others), high doses, procedures during dose escalation, and gastrointestinal comorbidities that delay gastric emptying raise risk of retained gastric contents. In most cases, clinicians can continue GLP1-RAs periprocedurally, although a 24-hour liquid diet may benefit high-risk patients. For colonoscopy, withholding GLP1-RAs may reduce the risk of inadequate bowel preparation, but further research should clarify the magnitude of this risk."

Journal • Review • Constipation • Diabetes • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Hepatology • Metabolic Disorders • Obesity • Pancreatitis • Type 2 Diabetes Mellitus

METSAFE: Metabolic Surgery for Atrial Fibrillation Elimination (clinicaltrials.gov) - P4 | N=100 | Not yet recruiting | Sponsor: Ali Aminian | Trial completion date: Mar 2029 ➔ Mar 2030 | Initiation date: Aug 2025 ➔ Feb 2026 | Trial primary completion date: Dec 2028 ➔ Dec 2029

Trial completion date • Trial initiation date • Trial primary completion date • Cardiovascular • Genetic Disorders • Obesity

Response To "Superior Cerebrovascular Outcomes with Tirzepatide Versus Semaglutide: A Call for Cautious Interpretation of Observational Data". (PubMed, Cardiovasc Drugs Ther) - "SURPASS-CVOT, comparing tirzepatide to dulaglutide (not semaglutide) in general ASCVD populations, addresses a different clinical question and may lack power for post-CABG subgroup analysis. Our findings provide hypothesis-generating evidence for an understudied high-risk population, warranting further investigation in dedicated trials."

Journal • Observational data • Cardiovascular • Diabetes • Metabolic Disorders

Various GLP-1 Receptor Agonist Preference Use with a Special Focus on Oral and Subcutaneous Forms in Poland. (PubMed, Healthcare (Basel)) - "Obesity was diagnosed in 78% of all patients, most often in the groups using liraglutide and tirzepatide. The highest percentage of patients with type 2 diabetes was observed in the dulaglutide group (67%), while the lowest was in the tirzepatide group (15%)... In the analysed group, GLP-1 RAs were most commonly used to treat obesity. The oral form of semaglutide was more frequently used in younger females with less aggravating medical history."

Journal • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Real-World Effectiveness of Finerenone Added to SGLT2 Inhibitor and GLP-1 Receptor Agonist Therapy in Individuals with Type 2 Diabetes and Chronic Kidney Disease. (PubMed, J Clin Med) - "Included individuals initiated finerenone between 1 August 2023, and 31 January 2025, and met the following criteria: estimated glomerular filtration rate (eGFR) of 25-60 mL/min/1.73 m2; urinary albumin-to-creatinine ratio (UACR) > 300 mg/g; and a history of ≥12 weeks of SGLT2i (empagliflozin or dapagliflozin) and GLP-1 RA (liraglutide, dulaglutide, or semaglutide) use prior to finerenone initiation. Serum potassium increased by +0.34 mmol/L (p < 0.001). In adults with T2D and albuminuric CKD already receiving an SGLT2i and a GLP-1 RA, adding finerenone substantially reduced albuminuria."

Journal • Real-world evidence • Chronic Kidney Disease • Diabetes • Endocrine Disorders • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Divergent Risks of Hematologic Malignancies Associated with GLP-1 Receptor Agonists and SGLT2 Inhibitors: Preliminary Findings from a Pilot Network Meta-Analysis. (PubMed, Biomolecules) - "Our preliminary findings reveal distinct and agent-specific effects of GLP-1 receptor agonists on hematologic malignancy risk. While dulaglutide may elevate the risk, tirzepatide appears protective, particularly against lymphoma. These results call for further long-term mechanistic studies to clarify causality and underlying pathways."

Clinical • Journal • Retrospective data • Review • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Oncology